MLchartDataset catalogue

Trk inhibitor LOXO-101

Term · Oncology and biomedicine · MLC-T-ONC-008920

A drug used to treat adults and children with certain types of solid tumors that have spread or cannot be removed by surgery and have the NTRK gene fusion. It is also being studied in the treatment of other types of cancer. Trk inhibitor LOXO-101 blocks the TRK protein, which may help keep cancer cells from growing and may kill them. It is a type of tyrosine kinase inhibitor. Also called larotrectinib sulfate, LOXO-101, and Vitrakvi.

Table 1. Record
IdentifierMLC-T-ONC-008920
FieldOncology and biomedicine
Synonymslarotrectinib sulfate; LOXO-101; Vitrakvi
ReferencesNCI Dictionary of Cancer Terms
Record as JSON
{
  "id": "MLC-T-ONC-008920",
  "term": "Trk inhibitor LOXO-101",
  "field": "Oncology and biomedicine",
  "definition": "A drug used to treat adults and children with certain types of solid tumors that have spread or cannot be removed by surgery and have the NTRK gene fusion. It is also being studied in the treatment of other types of cancer. Trk inhibitor LOXO-101 blocks the TRK protein, which may help keep cancer cells from growing and may kill them. It is a type of tyrosine kinase inhibitor. Also called larotrectinib sulfate, LOXO-101, and Vitrakvi.",
  "synonyms": [
    "larotrectinib sulfate",
    "LOXO-101",
    "Vitrakvi"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms"
  ],
  "url": "https://mlchart.com/terminology/oncology/trk-inhibitor-loxo-101/"
}

Record 16,744 of 17,717 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.